“Everyone Knows” the Fed Won’t Cut Rates—But Wall Street Might Be Dead Wrong

Here’s a dangerous phrase in investing: “Everyone knows.” Everyone knows internet stocks don’t need profits. Everyone knows real estate only goes up. Everyone knows Bitcoin’s hitting a million bucks.

The problem? When everyone believes the same thing, there’s nobody left on the other side of the trade. No sellers. No friction. Just a one-way ticket to Bubble City, population: you.

  • Special: Trump's New AI Executive Order
  • Right now, Wall Street’s collective “everyone knows” is that the Fed won’t cut rates in 2026. Regional bank presidents are even whispering about hiking them. So naturally, investors have stampeded into mega-cap cash machines like Apple and Google—companies that laugh at high borrowing costs. The Magnificent Seven now make up 35% of the S&P 500, up from 20% just three years ago.

    But here’s the thing: the jobs market is weaker than the headlines suggest. Consumer spending is slowing. And if things get dicey, the Fed might be forced to cut rates anyway—even with sticky inflation hanging around.

    That’s where small-cap stocks come in. These are companies that need cheap money to grow. When rates fall, they explode. And right now, they’re criminally underpriced because Wall Street doesn’t even know they exist.

    Take TOYO, a Tokyo-based solar manufacturer. Solar’s having a moment—the U.S. expects it to power 51% of new electricity generation this year. TOYO makes next-gen solar cells and just became the biggest non-Chinese producer that qualifies for U.S. tax credits. Revenues are expected to jump 95% this year. The stock trades at 5X forward earnings. If rates drop, this thing could run.

  • Special: How to Turn ChatGPT Into a Royalty Machine
  • Or Ardmore Shipping. The Strait of Hormuz closure has tanker rates up 3X. Ardmore owns 25 ships and has printed cash in 13 of the last 15 years. With rates potentially falling, their debt costs plummet. The stock trades at 12.5X earnings with $21 per share in net asset value backing it. That’s a steal.

    Then there’s Nautilus Biotech—a pre-revenue moonshot building a protein analysis platform that could revolutionize drug development. It’s risky. It could go to zero. But if they hit their timeline and rates fall? This is the kind of stock that makes portfolios.

    The bottom line: December’s a long way off. Plenty can happen. And when the consensus is this crowded, the real money often hides in the places nobody’s looking.